Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 Days Inventory is 138.81 as of Mar. 2026, which is 33% below its 10-year median of 206.62. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 59.44% on this metric.
The historical rank and industry rank for ANI Pharmaceuticals's Days Inventory or its related term are showing as below:
FRA:BSFA'
s Days Inventory Range Over the Past 10 Years
Min: 142.98 Med: 206.62 Max: 258.48
Current: 142.98
During the past 13 years, ANI Pharmaceuticals's highest Days Inventory was 258.48. The lowest was 142.98. And the median was 206.62.
FRA:BSFA's Days Inventory is ranked better than 59.44% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.005
vs FRA:BSFA: 142.98
ANI Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (174.05) to Mar. 2026 (138.81).
Inventory Turnover measures how fast the company turns over its inventory within a year.
ANI Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.66.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ANI Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.60.
ANI Pharmaceuticals (FRA:BSFA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ANI Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ANI Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ANI Pharmaceuticals Days Inventory Related Terms
ANI Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BSFA vs TRLV, AMLX, XERS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (FRA:BSFA) has a Days Inventory of 138.81 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ANI Pharmaceuticals and its competitors. This is 33% below median its historical median of 206.62. Over the past decade, ANI Pharmaceuticals' Days Inventory has ranged from 142.98 to 258.48. According to the industry distribution chart, ANI Pharmaceuticals ranks #374 out of 922 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is ANI Pharmaceuticals' Days Inventory too high?
ANI Pharmaceuticals' current Days Inventory of 138.81 is 33% below median its 10-year median of 206.62. Over the past 10 years, this metric has ranged from a low of 142.98 to a high of 258.48. The Drug Manufacturers industry median Days Inventory is 165.01. ANI Pharmaceuticals' value of 138.81 is 15.9% below this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #374 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Days Inventory compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #374 out of 922 companies for Days Inventory. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 165.01. ANI Pharmaceuticals' value of 138.81 is 15.9% below this benchmark. Historically, ANI Pharmaceuticals' own Days Inventory has ranged from 142.98 to 258.48 over the past decade. While the company's 10-year median is 206.62 vs. the industry median of 165.01, ANI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.01, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current Days Inventory of 138.81 is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current Days Inventory is 138.81, which is 33% below median its own 10-year median of 206.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current Days Inventory is 138.81, which is 33% below median its 10-year median of 206.62 and 15.9% below the Drug Manufacturers industry median of 165.01. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Days Inventory is 138.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
Days Inventory: 138.81 (33% below median its 10-year median of 206.62)
GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
Industry Position: 15.9% below the Drug Manufacturers median (#374 of 922)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
